BIOMAT Database Logo BIOMAT Database Logo

Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus. 2023

Habib Yaribeygi, and Mina Maleki, and Thozhukat Sathyapalan, and Tannaz Jamialahmadi, and Amirhossein Sahebkar
Chronic Kidney Disease Research Center, Semnan University of Medical Sciences, Semnan, Iran.

Type 2 diabetes mellitus (T2DM) is one of the main causes of mortality and morbidity worldwide. It leads to various long-term complications such as diabetic nephropathy. Diabetes nephropathy is the leading cause of renal failure in patients with chronic kidney diseases undergoing hemodialysis. Hence preventing the development and progression of diabetic nephropathy is one of the main goals in the management of patients with type 2 diabetes. Sodium-glucose cotransporter 2 inhibitors of empagliflozin is a potent anti-hyperglycemic agents. In addition, it has been shown to have some pharmacologic potentials to provide renoprotective effects in patients with T2DM. In the current study, we review the available clinical data on the potential renoprotective effects of this drug from a mechanistic and molecular viewpoint.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D003928 Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE. Diabetic Glomerulosclerosis,Glomerulosclerosis, Diabetic,Diabetic Kidney Disease,Diabetic Nephropathy,Intracapillary Glomerulosclerosis,Kimmelstiel-Wilson Disease,Kimmelstiel-Wilson Syndrome,Nodular Glomerulosclerosis,Diabetic Kidney Diseases,Glomerulosclerosis, Nodular,Kidney Disease, Diabetic,Kidney Diseases, Diabetic,Kimmelstiel Wilson Disease,Kimmelstiel Wilson Syndrome,Nephropathies, Diabetic,Nephropathy, Diabetic,Syndrome, Kimmelstiel-Wilson
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077203 Sodium-Glucose Transporter 2 Inhibitors Compounds that inhibit SODIUM-GLUCOSE TRANSPORTER 2. They lower blood sugar by preventing the reabsorption of glucose by the kidney and are used in the treatment of TYPE 2 DIABETES MELLITUS. Gliflozin,SGLT-2 Inhibitor,SGLT2 Inhibitor,Sodium-Glucose Transporter 2 Inhibitor,Gliflozins,SGLT-2 Inhibitors,SGLT2 Inhibitors,Inhibitor, SGLT-2,Inhibitor, SGLT2,SGLT 2 Inhibitor,SGLT 2 Inhibitors,Sodium Glucose Transporter 2 Inhibitor,Sodium Glucose Transporter 2 Inhibitors

Related Publications

Habib Yaribeygi, and Mina Maleki, and Thozhukat Sathyapalan, and Tannaz Jamialahmadi, and Amirhossein Sahebkar
Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.
February 2017, Diabetes therapy : research, treatment and education of diabetes and related disorders,
Habib Yaribeygi, and Mina Maleki, and Thozhukat Sathyapalan, and Tannaz Jamialahmadi, and Amirhossein Sahebkar
Empagliflozin (Jardiance) for Type 2 Diabetes Mellitus.
December 2016, American family physician,
Habib Yaribeygi, and Mina Maleki, and Thozhukat Sathyapalan, and Tannaz Jamialahmadi, and Amirhossein Sahebkar
Empagliflozin: a review of its use in patients with type 2 diabetes mellitus.
October 2014, Drugs,
Habib Yaribeygi, and Mina Maleki, and Thozhukat Sathyapalan, and Tannaz Jamialahmadi, and Amirhossein Sahebkar
Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus.
October 2016, Clinical therapeutics,
Habib Yaribeygi, and Mina Maleki, and Thozhukat Sathyapalan, and Tannaz Jamialahmadi, and Amirhossein Sahebkar
Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
September 2015, Drugs of today (Barcelona, Spain : 1998),
Habib Yaribeygi, and Mina Maleki, and Thozhukat Sathyapalan, and Tannaz Jamialahmadi, and Amirhossein Sahebkar
Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.
April 2022, Diabetes research and clinical practice,
Habib Yaribeygi, and Mina Maleki, and Thozhukat Sathyapalan, and Tannaz Jamialahmadi, and Amirhossein Sahebkar
Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension.
April 2019, Circulation,
Habib Yaribeygi, and Mina Maleki, and Thozhukat Sathyapalan, and Tannaz Jamialahmadi, and Amirhossein Sahebkar
Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial.
August 2021, Journal of the American Heart Association,
Habib Yaribeygi, and Mina Maleki, and Thozhukat Sathyapalan, and Tannaz Jamialahmadi, and Amirhossein Sahebkar
Effect of empagliflozin in peripheral diabetic neuropathy of patients with type 2 diabetes mellitus.
April 2024, Medicina clinica,
Habib Yaribeygi, and Mina Maleki, and Thozhukat Sathyapalan, and Tannaz Jamialahmadi, and Amirhossein Sahebkar
Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.
February 2020, Digestive diseases and sciences,
Copied contents to your clipboard!